• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

强化多因素干预治疗伴微量白蛋白尿的 2 型糖尿病患者可带来长期肾脏获益。

Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.

机构信息

Slagelse Hospital, Slagelse, Denmark; University of Southern Denmark, Odense, Denmark; Steno Diabetes Center, Gentofte, Denmark.

Slagelse Hospital, Slagelse, Denmark; University of Southern Denmark, Odense, Denmark.

出版信息

Kidney Int. 2017 Apr;91(4):982-988. doi: 10.1016/j.kint.2016.11.023. Epub 2017 Feb 7.

DOI:10.1016/j.kint.2016.11.023
PMID:28187983
Abstract

In the present post hoc analyses we studied the impact of intensified, multifactorial treatment on renal outcomes in patients with type 2 diabetes and microalbuminuria enrolled in the Steno-2 Study. Outcome measures were progression to macroalbuminuria, decline in the glomerular filtration rate (GFR), and development of end stage renal disease (ESRD). In total, 160 patients with type 2 diabetes and microalbuminuria were recruited and assigned to conventional or intensified therapy targeting multiple risk factors. The mean duration of the intervention was 7.8 years after which all patients were offered intensified therapy over a total follow-up up to 21 years on albuminuria, GFR, ESRD and mortality. Progression to macroalbuminuria was significantly reduced in the intensive-therapy group with a hazard ratio of 0.51 [95% confidence interval 0.32, 0.84]. The decline in GFR was significantly different with 3.1 ml/min/year in the intensive-therapy group compared to 4.0 in the conventional-therapy group. Progression to ESRD trended towards a decreased hazard with an adjusted ratio in the intensive group of 0.36 [0.12, 1.05]. ESRD combined with death had a significantly reduced hazard ratio of 0.53 [0.35, 0.8]. Thus, intensified, multifactorial treatment slowed progression in nephropathy and renal function loss reducing the risk of ESRD.

摘要

在本事后分析中,我们研究了强化、多因素治疗对 2 型糖尿病和微量白蛋白尿患者的肾脏结局的影响,这些患者参加了 Steno-2 研究。结局测量指标为进展为大量白蛋白尿、肾小球滤过率(GFR)下降和终末期肾病(ESRD)的发展。总共招募了 160 名患有 2 型糖尿病和微量白蛋白尿的患者,并将其分配到常规或强化治疗组,针对多个危险因素进行治疗。干预的平均持续时间为 7.8 年,之后所有患者均接受强化治疗,在白蛋白尿、GFR、ESRD 和死亡率方面的总随访时间长达 21 年。强化治疗组的大量白蛋白尿进展显著减少,风险比为 0.51[95%置信区间 0.32,0.84]。强化治疗组的 GFR 下降明显不同,为 3.1ml/min/年,而常规治疗组为 4.0ml/min/年。进展为 ESRD 的风险呈下降趋势,强化治疗组的调整比值为 0.36[0.12,1.05]。ESRD 合并死亡的风险比显著降低,为 0.53[0.35,0.8]。因此,强化、多因素治疗减缓了肾病和肾功能丧失的进展,降低了 ESRD 的风险。

相似文献

1
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.强化多因素干预治疗伴微量白蛋白尿的 2 型糖尿病患者可带来长期肾脏获益。
Kidney Int. 2017 Apr;91(4):982-988. doi: 10.1016/j.kint.2016.11.023. Epub 2017 Feb 7.
2
Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death.蛋白尿和估计肾小球滤过率作为糖尿病终末期肾病和死亡的预测指标。
Clin J Am Soc Nephrol. 2011 Oct;6(10):2444-51. doi: 10.2215/CJN.00580111. Epub 2011 Aug 18.
3
Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS.估算肾小球滤过率下降与2型糖尿病合并大量白蛋白尿患者的终末期肾病风险相关:一项来自日本糖尿病肾病协作研究(JDNCS)的观察性研究
Clin Exp Nephrol. 2018 Apr;22(2):377-387. doi: 10.1007/s10157-017-1467-9. Epub 2017 Sep 9.
4
Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients.蛋白尿和肾小球滤过率降低对预测2型糖尿病患者的肾脏结局的作用
Nephrology (Carlton). 2015 Aug;20(8):531-8. doi: 10.1111/nep.12446.
5
Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors.改善危险因素控制可提高 2 型糖尿病肾病患者的生存率和肾脏预后。
Diabetes Care. 2014 Jun;37(6):1660-7. doi: 10.2337/dc13-2036. Epub 2014 Mar 12.
6
Combined diabetes-renal multifactorial intervention in patients with advanced diabetic nephropathy: Proof-of-concept.晚期糖尿病肾病患者的糖尿病 - 肾脏联合多因素干预:概念验证
J Diabetes Complications. 2017 Mar;31(3):624-630. doi: 10.1016/j.jdiacomp.2016.11.019. Epub 2016 Dec 8.
7
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.2型糖尿病合并微量白蛋白尿患者多因素干预所获寿命延长:斯滕诺-2随机试验21年随访
Diabetologia. 2016 Nov;59(11):2298-2307. doi: 10.1007/s00125-016-4065-6. Epub 2016 Aug 16.
8
Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes.蛋白尿和肾小球滤过率对日本2型糖尿病患者肾脏和心血管事件以及全因死亡率的临床影响。
Clin Exp Nephrol. 2014 Aug;18(4):613-20. doi: 10.1007/s10157-013-0879-4. Epub 2013 Oct 17.
9
Progression of nephropathy in type 2 diabetic patients.2型糖尿病患者肾病的进展
Kidney Int. 2004 Oct;66(4):1596-605. doi: 10.1111/j.1523-1755.2004.00925.x.
10
Increased risk of renal deterioration associated with low e-GFR in type 2 diabetes mellitus only in albuminuric subjects.仅在蛋白尿患者中,2型糖尿病患者的估算肾小球滤过率(e-GFR)降低与肾脏恶化风险增加相关。
Intern Med. 2009;48(9):657-63. doi: 10.2169/internalmedicine.48.1865. Epub 2009 May 1.

引用本文的文献

1
Global challenges in diabetes research and care: which way forward? An appraisal from the EASD Global Council.糖尿病研究与照护中的全球挑战:何去何从?欧洲糖尿病研究协会全球委员会的评估
Diabetologia. 2025 Sep 10. doi: 10.1007/s00125-025-06504-5.
2
Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative Care.《肾脏病:改善全球预后》慢性肾脏病糖尿病管理实施峰会建议:从初级护理到数据驱动的协作护理
Kidney Int Rep. 2025 Jun 18;10(8):2551-2565. doi: 10.1016/j.ekir.2025.06.010. eCollection 2025 Aug.
3
Development of a nomogram for predicting renal survival in patients with biopsy-proven diabetic nephropathy.
用于预测经活检证实的糖尿病肾病患者肾脏存活率的列线图的开发。
Front Endocrinol (Lausanne). 2025 Mar 27;16:1532494. doi: 10.3389/fendo.2025.1532494. eCollection 2025.
4
Physical activity and renal outcome in diabetic and non-diabetic patients with chronic kidney disease stage G3b to G5.慢性肾脏病 G3b 至 G5 期的糖尿病和非糖尿病患者的体力活动与肾脏结局。
Sci Rep. 2024 Nov 2;14(1):26378. doi: 10.1038/s41598-024-77497-1.
5
Education programmes for people with chronic kidney disease and diabetes.针对慢性肾脏病和糖尿病患者的教育计划。
Cochrane Database Syst Rev. 2024 Aug 22;8(8):CD007374. doi: 10.1002/14651858.CD007374.pub3.
6
Rate and risk factors of kidney function decline among South Asians with type 2 diabetes: analysis of the CARRS Trial.2 型糖尿病南亚人群肾功能下降的速率和风险因素:CARRS 试验分析。
BMJ Open Diabetes Res Care. 2024 Aug 16;12(4):e004218. doi: 10.1136/bmjdrc-2024-004218.
7
Clinical Outcomes Among High-Risk Primary Care Patients With Diabetic Kidney Disease: Methodological Challenges and Results From the STOP-DKD Study.高危初级保健患者伴糖尿病肾病的临床结局:来自 STOP-DKD 研究的方法学挑战和结果。
Med Care. 2024 Oct 1;62(10):660-666. doi: 10.1097/MLR.0000000000002043. Epub 2024 Jul 18.
8
Risk factors for chronic kidney disease progression over 20 years for primary prevention in Japanese individuals at a preventive medicine research center: Focus on the influence of plasma glucose levels.20 年期间日本个体在预防医学研究中心进行原发性预防的慢性肾脏病进展的风险因素:关注血浆葡萄糖水平的影响。
J Diabetes Investig. 2024 Oct;15(10):1434-1443. doi: 10.1111/jdi.14259. Epub 2024 Jul 2.
9
Mitochondrial metabolic reprogramming in diabetic kidney disease.糖尿病肾病中的线粒体代谢重编程。
Cell Death Dis. 2024 Jun 24;15(6):442. doi: 10.1038/s41419-024-06833-0.
10
The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus.胰高血糖素样肽-1激动剂司美格鲁肽每周给药对2型糖尿病成年患者肾脏结局的影响。
J Family Med Prim Care. 2024 Feb;13(2):532-536. doi: 10.4103/jfmpc.jfmpc_1031_23. Epub 2024 Mar 6.